about
Postibrutinib outcomes in patients with mantle cell lymphoma.The role of infectious agents, antibiotics, and antiviral therapy in the treatment of extranodal marginal zone lymphoma and other low-grade lymphomas.Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemiaThe phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways.Antibody therapy for acute lymphoblastic leukemia.Adult lymphoblastic lymphoma.Ocular adnexal lymphoma: assessment of a tumor-node-metastasis staging system.Novel targeted therapies in acute lymphoblastic leukemia.Uveal lymphoma: clinical features, diagnostic studies, treatment selection, and outcomes.Clinical characteristics of 95 patients with ocular adnexal and uveal lymphoma: treatment outcomes in extranodal marginal zone subtype.Recent developments in the implementation of novel designs for early-phase combination studies.Protease-activated receptor stimulation activates a Ca2+-independent phospholipase A2 in bladder microvascular endothelial cells.Single agent lenalidomide induces a response in refractory T-cell posttransplantation lymphoproliferative disorder.Measurement of the motility of endothelial cells in confluent monolayers.De Novo polycythaemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 cloneProstacyclin Production in Tryptase and Thrombin Stimulated Human Bladder Endothelial Cells: Effect of Pretreatment With Phospholipase A2 and Cyclooxygenase InhibitorsOutcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failureAssessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK inhibition as an Effective Strategy
P50
Q30277756-49EDB9A9-2A0C-4043-9443-904BF7BB94EFQ30299948-9217A1CB-B293-4DB7-9DC8-EC3557C2C32AQ36834079-4D196463-7B11-4084-88CE-83331ECCE556Q37200384-267E7A40-6DD1-4ABF-8559-DD33BDA00044Q37994136-BDE0A79A-02D7-44C4-90EB-8F065C747BBCQ38046048-FED4F330-8A72-4FB1-98FC-799FF7A02FF8Q38105759-21DB7F54-C9BA-4713-B700-93503CD75D3CQ38120551-A3389A3D-28D2-43CE-BDB0-B2D1E2D7DE0BQ38154351-4553C74C-F640-44C2-911F-F0CBEAF4BE57Q44992647-596266D4-E265-48E0-A6D0-142A7DAE39F5Q45009575-51CE89BB-BBE9-4FE3-8B6B-89615C6DB652Q45161363-0AB4937A-4884-4A21-8713-BEEB84A33897Q46656776-48A7B594-81A0-466B-9D24-FBC57E597CD1Q48597611-C3BA35F0-62E8-44ED-8C23-3458BC7808F6Q57452062-3F81150F-5906-4A3B-9F56-C1643A41F9B6Q57452063-E68933B4-D08F-4BF4-88AF-0597C253A192Q90375529-7B2F05AB-41DE-4E05-898B-5BCDD96F2F7EQ90538040-2CA2BD6E-AD55-48D0-AFCF-C3EF48141937
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Craig Portell
@ast
Craig Portell
@en
Craig Portell
@es
Craig Portell
@nl
type
label
Craig Portell
@ast
Craig Portell
@en
Craig Portell
@es
Craig Portell
@nl
prefLabel
Craig Portell
@ast
Craig Portell
@en
Craig Portell
@es
Craig Portell
@nl
P106
P1153
8274342200
P31
P496
0000-0002-9487-8345